Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV double-blind trial of Allergovit grasses versus Allergovit birch in pollen allergy using an environmental challenge chamber
2013-003095-12Phase 4Completed
- Sponsor
- Allergopharma
- Start
- Jan 2014
- Modality
- Peptides, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, double-blind trial of Allergovit Grasses and birch pollen allergoid in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Allergopharma. Primary endpoint: Specific treatment effect of Allergovit grasses. Started Jan 2014; status: completed.
02
Drugs
Allergovit Grassesbirch pollen allergoid
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2013-003095-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003095-12.